[go: up one dir, main page]

MX2015012681A - Composiciones y metodos para tratar patogenos fungicos y bacterianos. - Google Patents

Composiciones y metodos para tratar patogenos fungicos y bacterianos.

Info

Publication number
MX2015012681A
MX2015012681A MX2015012681A MX2015012681A MX2015012681A MX 2015012681 A MX2015012681 A MX 2015012681A MX 2015012681 A MX2015012681 A MX 2015012681A MX 2015012681 A MX2015012681 A MX 2015012681A MX 2015012681 A MX2015012681 A MX 2015012681A
Authority
MX
Mexico
Prior art keywords
compositions
methods
bacterial pathogens
treating fungal
fungal
Prior art date
Application number
MX2015012681A
Other languages
English (en)
Inventor
E Edwards John Jr
S Ibrahim Ashraf
R Yeaman Michael
G Filler Scott
P Hennesey John Jr
Original Assignee
Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct filed Critical Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct
Publication of MX2015012681A publication Critical patent/MX2015012681A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/165—Yeast isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/72—Candida
    • C12R2001/725—Candida albicans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención presenta HYR1 como objetivo de vacuna y como una estrategia profiláctica para combatir candidiasis diseminada.
MX2015012681A 2013-03-15 2014-03-14 Composiciones y metodos para tratar patogenos fungicos y bacterianos. MX2015012681A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789091P 2013-03-15 2013-03-15
PCT/US2014/028521 WO2014144211A2 (en) 2013-03-15 2014-03-14 Compositions and methods for treating fungal and bacterial pathogens

Publications (1)

Publication Number Publication Date
MX2015012681A true MX2015012681A (es) 2018-05-17

Family

ID=51538308

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012681A MX2015012681A (es) 2013-03-15 2014-03-14 Composiciones y metodos para tratar patogenos fungicos y bacterianos.

Country Status (12)

Country Link
US (2) US10130691B2 (es)
EP (1) EP2968497B1 (es)
JP (2) JP6591961B2 (es)
CN (1) CN105407915A (es)
AU (1) AU2014227748B2 (es)
BR (1) BR112015022963A8 (es)
CA (1) CA2906771A1 (es)
EA (1) EA030005B1 (es)
MD (1) MD20150098A2 (es)
MX (1) MX2015012681A (es)
RU (1) RU2717306C2 (es)
WO (1) WO2014144211A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US10130691B2 (en) 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
JP2019507759A (ja) * 2016-03-09 2019-03-22 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット
CN112203684A (zh) * 2018-04-10 2021-01-08 海港医学中心洛杉矶生物医学研究所 耳念珠菌感染的治疗方法
WO2020174366A1 (en) 2019-02-28 2020-09-03 Universidade Do Minho Antisense oligomers for controlling candida albicans infections
US20220354935A1 (en) * 2021-04-21 2022-11-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Vaccination against fungal epitopes to prevent inflammatory bowel diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346074A (en) 1978-08-24 1982-08-24 National Research Development Corp. Pasteurellosis vaccines
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995031998A1 (en) 1994-05-23 1995-11-30 The Research & Development Institute, Inc. Candida albicans adhesin as a vaccine
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
EP0831897B1 (en) 1995-06-07 2001-03-28 Pfizer Inc. In ovo vaccination against coccidiosis
US6288214B1 (en) 1996-05-16 2001-09-11 Texas A&M University Systems Collagen binding protein compositions and methods of use
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6248329B1 (en) 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US8541008B2 (en) 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
US20060083750A1 (en) 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US7067138B1 (en) 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
ES2335979T3 (es) 2001-09-14 2010-04-07 Cytos Biotechnology Ag Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso.
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
DK1461442T3 (en) 2001-11-30 2017-12-04 Amgen Fremont Inc Transgenic animals with human Ig lambda light chain genes
JP4495586B2 (ja) 2002-05-21 2010-07-07 シェーリング−プラウ・リミテッド Ｓｐｏｒｏｚｏｅａｓｐ．のインビトロ培養のための方法およびそれらの使用
US7241613B1 (en) 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
KR100785601B1 (ko) 2003-11-21 2007-12-14 화이자 프로덕츠 인크. 백신 아쥬반트로서의 항생제의 용도
US20050287146A1 (en) 2003-12-19 2005-12-29 Joseph Patti Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
WO2006036817A2 (en) 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
CA2489194A1 (en) 2004-12-03 2006-06-03 Guilhem Janbon Polypeptides involved in candida biofilm formation and uses thereof
WO2007126813A2 (en) * 2006-03-29 2007-11-08 Inhibitex, Inc. Cross-reactive monoclonal antibodies recognizing als family proteins
US7732187B2 (en) 2006-04-17 2010-06-08 Intervet Inc. Recombinant attenuated clostridium organisms and vaccine
US20080311135A1 (en) 2007-05-22 2008-12-18 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
CA2725361C (en) 2008-05-29 2017-05-16 Intervet International B.V. Coccidiosis vaccines
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
BR112012000036A2 (pt) * 2009-07-03 2018-04-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center hyr1 como um alvo para imunização ativa e passiva contra candida
US20140082769A1 (en) * 2011-03-11 2014-03-20 Joost Schymkowitz Molecules and methods for inhibition and detection of proteins
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
EP2734229B1 (en) * 2011-07-22 2019-01-02 Novadigm Therapeutics, Inc. Methods and copositions for vaccinating against staphylococcus aureus
AU2012308281A1 (en) 2011-09-14 2014-04-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1-derived compositions and methods of treatment using same
US10130691B2 (en) 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
WO2014144222A2 (en) 2013-03-15 2014-09-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods of treating fungal and bacterial pathogens
WO2014144024A1 (en) 2013-03-15 2014-09-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 compositions and methods for treating fungal and bacterial pathogens
GB201503812D0 (en) 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
JP2019507759A (ja) 2016-03-09 2019-03-22 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット

Also Published As

Publication number Publication date
RU2015144090A (ru) 2017-04-19
US10130691B2 (en) 2018-11-20
JP2016515516A (ja) 2016-05-30
EA201591808A1 (ru) 2016-02-29
AU2014227748B2 (en) 2019-02-14
JP2019110918A (ja) 2019-07-11
JP6591961B2 (ja) 2019-10-16
BR112015022963A2 (pt) 2017-11-14
CN105407915A (zh) 2016-03-16
CA2906771A1 (en) 2014-09-18
WO2014144211A2 (en) 2014-09-18
WO2014144211A3 (en) 2015-11-19
BR112015022963A8 (pt) 2018-01-16
EP2968497A4 (en) 2016-11-30
RU2717306C2 (ru) 2020-03-19
EA030005B1 (ru) 2018-06-29
MD20150098A2 (ro) 2016-02-29
US20190030141A1 (en) 2019-01-31
EP2968497A2 (en) 2016-01-20
AU2014227748A1 (en) 2015-10-08
EP2968497B1 (en) 2020-08-12
US20160030534A1 (en) 2016-02-04
WO2014144211A8 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
MX2021004479A (es) Agentes biologicos y su uso en plantas.
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
EP3129035A4 (en) Compositions and methods for induction of th17 cells
MX2021013665A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
EP3331582A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRANSPLANTATION CELLS
EP3152303A4 (en) Soluble bacterial and fungal proteins and methods and uses thereof in inhibiting and dispersing biofilm
MX2013012165A (es) Composicion y metodo para mejorar una respuesta inmune.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
MX2015012681A (es) Composiciones y metodos para tratar patogenos fungicos y bacterianos.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
HK1258276A1 (zh) 用於治疗hiv的化合物和组合
EP3145516A4 (en) Methods and compositions for treating malignancies with dendritic cells
EP3268010A4 (en) Compositions and methods for treating bacterial infection
ZA201900070B (en) Antibodies with low immunogenicity and uses thereof
PH12017501022A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
IL287622A (en) Preparations and methods for treating fungal infections
ZA201503474B (en) Compositions and methods for treating bacterial infections
UA115305C2 (uk) Композиції hyr1-похідних і способи лікування ними
SMT201900692T1 (it) Composizione per l'uso del trattamento delle infezioni batteriche
MX2017008612A (es) Películas envolventes con opacidad aumentada.
DK3336198T3 (en) Methods and uses for determination of fungal and/or bacterial infestation
HK1242965A1 (en) Apilimod for use in the treatment of colorectal cancer
AU2016904321A0 (en) Compositions and methods for prophylaxis or treatment
HK1226329A1 (en) Apilimod compositions and methods for using same